Insider · CIK 0001614936

Pomerantz Roger

Reports to the SEC for 7 companies · NESS ZIONA

sec.gov

Transactions

Companies

Filings

CIK

0001614936

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-06-10	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2025-04-10	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−500 sh	$0.50	−$250	0
2025-04-10	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−250 sh	$0.50	−$125	0
2025-04-10	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−250 sh	$0.50	−$125	0
2024-11-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	126,478
2024-11-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	18,069
2024-08-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	117,444
2024-08-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	27,103
2024-06-20	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2024-06-20	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.8K sh	—	—	18,750
2024-06-06	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2024-05-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,035 sh	—	—	108,410
2024-05-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,035 sh	—	—	36,137
2024-02-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	99,375
2024-02-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	45,172
2023-11-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	90,341
2023-11-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	54,206
2023-08-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	81,307
2023-08-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	63,240
2023-08-16	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2023-06-08	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2023-05-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,035 sh	—	—	72,273
2023-05-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,035 sh	—	—	72,274
2023-05-25	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2023-02-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	63,238
2023-02-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	81,309
2022-11-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	54,204
2022-11-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	90,343
2022-09-30	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+81K sh	—	—	81,000
2022-08-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	45,170
2022-08-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	99,377
2022-08-10	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30.3K sh	—	—	30,282
2022-06-09	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2022-05-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	36,136
2022-05-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	108,411
2022-02-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+9,034 sh	—	—	27,102
2022-02-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−9,034 sh	—	—	117,445
2022-02-15	CONTRAFECT CorpOptions (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+500K sh	$3.33	+$1.67M	500,000
2021-11-25	VIRXViracta Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+18.1K sh	—	—	18,068
2021-11-25	VIRXViracta Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−18.1K sh	—	—	126,479
2021-08-04	INDPIndaptus Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+41K sh	—	—	41,000
2021-04-08	CONTRAFECT CorpOptions (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+254K sh	—	—	254,000
2021-03-26	VIRXViracta Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+135K sh	—	—	135,000
2020-07-15	Intec Pharma Ltd.Stock Option (right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2019-06-28	Intec Pharma Ltd.Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-06-13	MCRBSeres Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2018-09-07	MCRBSeres Therapeutics, Inc.S Sale	Director	SSale	−1,810 sh	$9.00	−$16.3K	213,976
2018-09-06	MCRBSeres Therapeutics, Inc.S Sale	Director	SSale	−3,013 sh	$9.04	−$27.2K	215,786
2018-09-05	MCRBSeres Therapeutics, Inc.S Sale	Director	SSale	−9,505 sh	$9.12	−$86.7K	218,799
2018-07-20	Rubius Therapeutics, Inc.P Purchase	Director	PPurchase	+100 sh	$23.00	+$2,300	100

Recent filings

Accepted (ET)
Jun 114
Pomerantz Roger0001641172-25-014695
SEC(opens sec.gov)
Apr 114
Pomerantz Roger0001641172-25-003825
SEC(opens sec.gov)
Nov 274
Pomerantz Roger0000950170-24-131475
SEC(opens sec.gov)
Sep 124
Pomerantz Roger0000950170-24-106026
SEC(opens sec.gov)
Jun 244
Pomerantz Roger0000950170-24-076990
SEC(opens sec.gov)
Jun 74
Pomerantz Roger0001493152-24-023149
SEC(opens sec.gov)
May 294
Pomerantz Roger0000950170-24-066146
SEC(opens sec.gov)
Feb 274
Pomerantz Roger0001209191-24-004039
SEC(opens sec.gov)
Nov 284
Pomerantz Roger0001209191-23-056838
SEC(opens sec.gov)
Aug 294
Pomerantz Roger0001209191-23-047668
SEC(opens sec.gov)
Aug 184
Pomerantz Roger0001209191-23-046585
SEC(opens sec.gov)

Companies

Address

14 EINSTEIN STREET

NESS ZIONA, 7403618